Effector, Memory, and Dysfunctional CD8<sup>+</sup>T Cell Fates in the Antitumor Immune Response

John Reiser(University of Maryland, Baltimore), Arnob Banerjee(Johnson & Johnson (United States))

Journal of Immunology Research

January 1, 2016

10.1155/2016/8941260

Cited by 263

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

|The Lancet|2021|1.7k

Teclistamab in Relapsed or Refractory Multiple Myeloma

|New England Journal of Medicine|2022|1.2k

Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses

|Science|2007|852

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

|Journal of Clinical Oncology|2022|647

Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche

|The Journal of Immunology|2010|417